- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer; Gastric cancer
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Trastuzumab – July 2019
Trastuzumab: Powder for I.V. infusion 60 mg, 150 mg and 420 mg; Kanjinti®
Last updated
1 November 2019